Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1808 results
December 2023
-
Story Patient Perspectives
Shoulder to shoulder
People with breast cancer need better medicines that help reduce the risk and anxiety of it returning.
-
Media Release
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in… -
Key Release
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement… -
Featured NewsOur next era
Novartis poised to expand impact on human health as it begins next era.
-
Story Access to Healthcare
Beacon of Hope lights the way for a more equitable future
Sharing Key Insights and Lessons to Accelerate Progress.
-
Story People and Culture
How I found my true purpose at Novartis
-
Story People and Culture
Belonging here: How Novartis helped me come out as a transgender woman
-
Story People and Culture
Mentoring matters: how we grow together at Novartis
November 2023
-
Key Release
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent… -
Media Release
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-… -
Media Release
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria…